Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post...
Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post...
Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post Pounce System Use
surmodics宣佈對60名具有急性、亞急性或慢性肢體缺血癥狀的患者進行了早期子集分析，96.8%的程序性血流恢復，81.7%的受試者在Pounce系統使用後未接受額外的血栓栓塞去除治療
Early subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional thromboemboli removal treatment post Pounce System use.
對60名急性、亞急性或慢性肢體缺血癥狀患者進行的早期子集分析顯示，96.8%的程序性血流恢復，81.7%的受試者在Pounce系統使用後未接受額外的血栓栓塞去除治療。
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C.
Surmodics公司（納斯達克股票代碼：SRDX）是醫療保健行業中領先的醫療器械和體外診斷技術提供商，今天宣佈了其PROWL登記研究中60名真實世界急性、亞急性和慢性肢體缺血患者的早期結果，由Dean Ferrera博士在華盛頓特區舉行的第36屆TCt研討會上進行了報告。